Last reviewed · How we verify

NCT02811198

Pain, Reward, Attention and Neurocircuitry: Biomarkers of Suicidality

Completed Last updated 27 February 2026
What this trial tests

trial testing No intervention in Major Depressive Disorder in 97 participants. Completed in 30 January 2025.

Timeline
1 January 2017
Primary endpoint
9 December 2024
30 January 2025

Quick facts

Lead sponsorUnity Health Toronto
StatusCompleted
Study typeOBSERVATIONAL
Enrollment97
Start date1 January 2017
Primary completion9 December 2024
Estimated completion30 January 2025
Sites1 location across Canada

Drugs / interventions tested

Conditions studied

Sponsor

Unity Health Toronto — full company profile →

Who can join

Adults 18 to 70, any sex, with Major Depressive Disorder or Suicide. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The ultimate aim of this study is to identify a biomarker of suicide risk in MDD by measuring the "hedonic spectrum" (pain and reward responsivity), attention and its associated brain structures using brain scans (fMRI and DTI), as well as the stability of markers over time.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. The Canadian Biomarker Integration Network in Depression (CAN-BIND): magnetic resonance imaging protocols
    MacQueen GM, Hassel S, Arnott SR, Jean A, et al · · 2019 · cited 41× · PMID 30840428 · DOI 10.1503/jpn.180036

Verify or expand the search:

Other trials of No intervention

Trials testing the same drug.

Other recruiting trials for Major Depressive Disorder

Currently open trials in the same condition.

Other Unity Health Toronto trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02811198.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing